FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 12:24:08 04/06/2024 BST | ||
| 0.018 EUR | +12.50% |
|
| 1 month | -58.97% | ||
| 3 months | -98.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 0.018 | +12.50% |
| 03/06/24 | 0.016 | +23.08% |
| 31/05/24 | 0.013 | +18.18% |
| 30/05/24 | 0.011 | 0.00% |
| 29/05/24 | 0.011 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 12:24 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU0HF5 |
| ISIN | DE000SU0HF50 |
| Date issued | 10/10/2023 |
| Strike | 56.67 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.4 € |
|---|---|
| Lowest since issue | 0.01 € |
| Spread | 0.01 € |
| Spread % | 37.04% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.77
USD
Average target price
53.19
USD
Spread / Average Target
+27.35%
- Stock Market
- Certificates
- Certificat